美国的psilocybin微剂量:来自全国代表性调查的见解
Michelle Priest1, Beau Kilmer1, Rajeev Ramchand1
1Drug Policy Research Center, RAND, Santa Monica, CA, USA.
Addiction (Abingdon, England)
|March 8, 2026
概括
在美国,至少有840万成年人服用了微剂量的psilocybin. 最近的用户更有可能使用微剂量,通常是为了改善身体和心理健康,而不是为了娱乐.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 公共卫生 公共卫生
背景情况:
- псилоцибин在心理健康治疗方面越来越受到关注.
- 微量服用西是一种日益增长的趋势,但其流行病学尚不清楚.
- 这项研究解决了美国人口中关于psilocybin微剂量的缺乏数据的问题.
研究的目的:
- 为了确定美国成年人中psilocybin微剂量的患病率.
- 为了确定背后的动机 psilocybin 微剂量.
- 为了检查与psilocybin微剂量行为相关的因素.
主要方法:
- 对美国成年人进行了一项全国代表性的调查.
- 数据收集发生在2023年12月至2024年1月之间.
- 统计分析,包括多项逻辑模型,用于识别微剂量预测因素.
主要成果:
- 超过840万美国成年人服用了微剂量的psilocybin.
- 最近的psilocybin使用者 (去年) 更有可能使用微剂量.
- 与娱乐用途相比,微剂量者更有可能使用psilocybin用于身体和心理健康.
结论:
- 在美国成年人中,psilocybin微剂量普遍存在,大量人报告终身使用.
- 微量剂的动机主要与健康有关,使其与娱乐用途区别开来.
- 需要进一步的研究来了解微剂量的细微差别,包括用户的不确定性.
相关概念视频
Hallucinogens and Psychedelics
852
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
852
Fungal Phylum Microsporidia
661
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
661
Dosage Regimens: Partial Pharmacokinetic Parameters
244
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
244


